Research grade

COA available

Research Peptide

Ipamorelin 10mg

Selective GHS-R (ghrelin receptor) agonist — synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) First GHRP-receptor agonist with selectivity comparable to GHRH in published research CAS 170851-70-4 For in vitro GH secretagogue research only

$56.99 In stock

Research-Grade CompoundsManufactured to research-grade standards for laboratory research use only.

Discreet ShippingEvery order ships in plain, protective packaging.

In-House FulfillmentOrders are inspected, packed, and shipped directly by the Heritage Labs team.

Same-day dispatch on orders before 12:00 PM ET, Mon–Fri. Discreet, plain packaging.

In-House Fulfillment Orders are inspected, packed, and shipped directly by the Heritage Labs team.

View this compound’s Certificate of Analysis →

SSL 256-bit Secure Checkout

For laboratory research use only. Not for human or veterinary consumption. SKU IP10.

Overview

Product details.

Ipamorelin 10mg — Selective GH Secretagogue

When Raun et al. characterized Ipamorelin in 1998, they called it “the first growth hormone secretagogue receptor agonist with a selectivity for GH release similar to that displayed by GHRH” (European Journal of Endocrinology; PubMed 9849822). That selectivity is what defines this compound. Earlier GH-releasing peptides like GHRP-6 and GHRP-2 stimulated growth hormone but also pushed cortisol and prolactin levels higher. Ipamorelin does not — at GH-releasing concentrations in preclinical models, cortisol and prolactin remain at baseline levels.

Research-Grade Compounds

Manufactured to research-grade standards for laboratory research use only.

Discreet Shipping

Every order ships in plain, protective packaging.

In-House Fulfillment

Orders are inspected, packed, and shipped directly by the Heritage Labs team.

Specifications

Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular Formula	C₃₈H₄₉N₉O₅
Molecular Weight	711.85 g/mol
CAS Number	170851-70-4
PubChem CID	9831659
Purity	Research-grade
Form	Lyophilized powder
Quantity	10mg per vial

Pharmacology and Receptor Signaling

Ipamorelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily in anterior pituitary somatotrophs. The binding triggers a phospholipase C-mediated signaling cascade: IP3/DAG release, intracellular calcium mobilization, and protein kinase C (PKC) activation, culminating in growth hormone exocytosis. EC50 has been measured at 1.3 nmol/L in rat pituitary cell assays, with peak GH response occurring at approximately 40 minutes post-administration and a circulating half-life of approximately 2 hours (Gobburu et al., Pharmaceutical Research, 1999). What distinguishes ipamorelin from earlier GHS-R agonists (hexarelin, GHRP-6, GHRP-2) is its signaling selectivity. While those compounds activate GHS-R1a and also engage other pathways that elevate cortisol and prolactin, ipamorelin produces minimal cross-reactivity at GH-releasing concentrations. This selectivity makes it a valuable tool for researchers studying isolated GHS-R1a-mediated somatotroph activation without confounding adrenocorticotropic or lactotropic effects (Sinha et al., Transl Androl Urol, 2020; PMC7108996).

Research Applications Beyond Growth Hormone

The published literature on ipamorelin extends well beyond somatotroph activation. Svensson et al. examined its effects in bone mineral density studies using dual-energy X-ray absorptiometry (DEXA) and peripheral quantitative computed tomography (pQCT) in murine models, documenting changes in cortical and trabecular bone parameters (Svensson et al., The Journal of Endocrinology, 2000). Greenwood-Van Meerveld et al. investigated ipamorelin in postoperative gastric dysmotility models, where GHS-R1a agonism was associated with effects on gastric emptying rate and smooth muscle contractility (J Exp Pharmacol, 2012; PubMed 27186124). Additional research contexts include the study of GHS-R1a constitutive activity (the receptor signals at approximately 50% of maximal capacity even without ligand binding), inverse agonism, and biased signaling — areas where ipamorelin serves as a reference agonist for characterizing receptor pharmacology (Holst et al., Molecular Endocrinology, 2003; PubMed 12893882).

Key Research Applications

Selective GHS-R1a agonism and somatotroph signaling cascade characterization
Comparative secretagogue studies — selectivity profiling against GHRP-6, GHRP-2, hexarelin
Dual-pathway growth hormone axis research when paired with GHRH receptor agonists
GHS-R1a constitutive activity and biased agonism investigations
Bone metabolism and mineral density research models
Gastrointestinal motility and smooth muscle contractility studies

Ipamorelin + CJC-1295: Dual-Receptor Axis Research

Ipamorelin (GHS-R1a agonist) and CJC-1295 (GHRH receptor agonist) target different receptors within the same somatotropic axis. The published literature routinely examines these compounds together for dual-pathway somatotroph activation studies, as the two receptor systems converge on complementary intracellular signaling mechanisms in pituitary somatotrophs. Heritage Labs USA offers the CJC-IPA blend for researchers investigating this paired approach.

Frequently Paired With

CJC-1295 No DAC — Available as CJC-IPA Blend.
Tesamorelin 5mg — Available as Ipa/Tesa Blend.
Sermorelin 5mg — Alternative GHRH analog pairing.

Quality and testing

Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.

Storage

Lyophilized: Store at -20°C, protected from light and moisture
Reconstituted: 2-8°C, use within 30 days
Avoid repeated freeze-thaw cycles

References

Raun K, et al. European Journal of Endocrinology. 1998;139(5):552-561. PubMed 9849822
Sinha DK, et al. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMC7108996
Gobburu JVS, et al. Pharmaceutical Research. 1999;16:1412-1416.
Holst B, et al. Molecular Endocrinology. 2003;17(11):2201-2210. PubMed 12893882
Svensson J, et al. The Journal of Endocrinology. 2000.
Greenwood-Van Meerveld B, et al. J Exp Pharmacol. 2012;4:149-155. PubMed 27186124

For laboratory research use only. Not for human or veterinary use.

For laboratory research use only. Not for human or veterinary use. This product is not a drug or supplement and is not intended to diagnose, treat, cure, or prevent any disease.

FDA DISCLAIMER: All products are intended for research use only as defined by the FDA. Not for use in diagnostic procedures, human use, or veterinary use. Products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. All products sold by Heritage Labs are intended strictly for laboratory research, analytical, or in-vitro purposes only. Heritage Labs operates as a chemical supplier and is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act. Additionally, Heritage Labs is not classified as an outsourcing facility under Section 503B of the same Act. The statements on this website have not been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.